In Ontario, generic entry did not change the price of brand name drugs. However, the presence of at least four generic competitors was associated with a rise in brand name drug prices [72]. In British Columbia, prior to the 1987 legislative amendments, overall market prices reduced upon ...
A study from Canada examined whether IP changes over 3 decades affected the market exclusivity time of brand products on the Ontario Drug Benefit formulary [97]. Over the time period analysed, the study did not detect any systematic effects of Canada’s stronger pharmaceutical IP laws on market ...